drugset / Trial / NCT03773107
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Phase 1/2
Completed
12 enrolled
Wake Forest University Health Sciences
Amgen · collabIncyte Corporation · collabMultiple Myeloma Research Consortium · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of Phase I is to establish the maximum tolerated dose (MTD) of ruxolitinib in combination with carfilzomib and dexamethasone. The primary objective of phase II is to evaluate progression-free survival (PFS) at 4 months in multiple myeloma subjects who receive the combination treatment carfilzomib, dexamethasone, and ruxolitinib.
Timeline
- Start
- 2019-01-03
- Primary completion
- 2022-11-07
- Completion
- 2024-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 5 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 15 mg | Oral |
| Background | Carfilzomib | Other / unclassified | — | — |
| Background | Dexamethasone | Small molecule | — | — |